You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Claims for Patent: 10,881,657

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,881,657

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US16/359,958
Patent Claims:	1. A method of improving the efficacy of bupropion in treating major depression, comprising: orally administering a dosage form once a day or twice a day for at least 14 days, to a human being suffering from major depression, wherein bupropion and dextromethorphan are the only therapeutically active compounds in the dosage form, wherein the human being receives a daily dose of the bupropion that is about 200 mg to about 250 mg, wherein the daily dose of the bupropion is orally administered once a day or is a total of twice daily doses of the bupropion, wherein the human being receives a daily dose of the dextromethorphan that is about 60 mg to about 100 mg, wherein the daily dose of the dextromethorphan is orally administered once a day or is a total of twice daily doses of the dextromethorphan, wherein orally administering the bupropion in combination with the dextromethorphan is more effective in treating major depression than orally administering the same dosage regimen of the bupropion without the dextromethorphan; and wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 2. The method of claim 1, wherein about 40 mg to about 50 mg of the dextromethorphan is orally administered twice a day. 3. The method of claim 1, wherein about 45 mg of the dextromethorphan is orally administered twice a day. 4. The method of claim 1, wherein about 100 mg to about 120 mg of the bupropion is orally administered twice a day. 5. The method of claim 2, wherein about 105 mg of the bupropion is orally administered twice a day. 6. The method of claim 1, wherein the dosage form is orally administered for at least 35 days. 7. The method of claim 1, wherein the human being is suffering from treatment-resistant major depression. 8. The method of claim 1, wherein the dosage form is orally administered for at least 5 weeks. 9. The method of claim 1, wherein the dextromethorphan comprises a deuterium-modified dextromethorphan.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.